ACE Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4000
$ 6600
$ 8900

The Angiotensin-converting-enzyme (ACE) is involved in the Renin-angiotensin-aldosterone-system (RAAS) and stimulates the conversion of angiotensin-I to angiotensin-II. ACE inhibitors are competitive inhibitors of ACE, which prevent the conversion of angiotensin-I to angiotensin-II. Angiotensin-II acts as a potent vasoconstrictor that, when inhibited, can reduce blood pressure by dilating vessels and decreasing aldosterone secretion. Actions of angiotensin-II and aldosterone also lead to adverse cardiac remodeling. ACE inhibitors prevent adverse cardiac remodeling by reducing the concentrations of angiotensin-II and aldosterone. ACE inhibitors are widely used by clinicians/physicians to treat and manage hypertension, heart failure, stroke, coronary heart disease, patients with chronic kidney disease, and diabetes mellitus. Sanofi S.A., Gedeon Richter, Pfizer, Bristol-Myers Squibb, Novartis, and Merck (MSD) are the key players in the market for the drug class ACE inhibitor.

Key Developments:

  • In Apr 2020, the University of Athens conducted a study to observe the effect of ACE inhibitors and the Sacubitril-Valsartan complex in bone marrow patients by assessing cardiovascular and endothelial parameters in order to search for a potential protective role.
  • In Nov 2022, Novartis conducted an effective study of ARNI on ventricular arrhythmia in HFrEF patients with implanted ICD or CRT-D in China.

Approved Drug Molecules and Brand Names for ACE Inhibitors:

  • ALTACE (Ramipril)
  • VASOTEC (Enalapril)
  • COVERSYL (Perindopril arginine)
  • CAPOTEN (Captopril)
  • LOTENSIN (Benazepril)
  • MAVIK (Trandolapril)
  • LOTREL (Amlodipine/Benazepril)
  • MONOPRIL (Fosinopril)
  • TRIPLIXAM (Perindopril arginine/Amlodipine/Indapamide)
  • ACCUPRIL (Quinapril hydrochloride)
  • COVERAM (Perindopril arginine+Amlodipine)
  • LISONORM (Amlodipine/Lisinopril)
  • TANATRIL (Imidapril)
  • OCADRIK (Trandolapril/Verapamil)

Drugs under the Pipeline for ACE Inhibitors:

Cosimprel (Bisoprolol/Perindopril)

Enalapril Orodispersible Minitablet

Clinical Activity and Developments of ACE Inhibitors:

Currently, there are more than 20 drug products for ACE inhibitors, including both approved drugs in the market and drugs in clinical development phases.

  • In Jan 2020, Pfizer conducted a phase-II clinical trial to observe the efficacy of Ramic (Ramipril) in heart patients with COVID-19 infections.


Molecule Name

Number of Studies

Cosimprel (Bisoprolol/Perindopril)


Enalapril Orodispersible Minitablet


Target Indication Analysis of ACE Inhibitors:

ACE inhibitors are useful as adjunctive therapy in systolic heart failure patients who also have a history of myocardial infarction. ACE inhibitors can be used to treat hypertension either alone or in conjunction with other anti-hypertensives to lower blood pressure. It is also recommended as part of a regimen in patients with hypertension and chronic stable angina if there is a history of left ventricular dysfunction, diabetes mellitus, or chronic kidney disease. ACE inhibitors should be initiated within 24 hours of ST-elevated myocardial infarction, specifically in patients with anterior myocardial infarction, heart failure, or left ventricular ejection fraction of 40% or less.  The addition of an ACE inhibitor has shown a significant reduction in serum creatinine in hypertensive and normotensive patients with albuminuria. ACE inhibitor therapy has shown a significant decrease in the progression of diabetic nephropathy.

Frequently Asked Questions

GALTACE (Ramipril), VASOTEC (Enalapril), COVERSYL (Perindopril arginine), CAPOTEN (Captopril), LOTENSIN (Benazepril), MAVIK (Trandolapril), are the few approved ACE inhibitors.

The global death burden for cardiovascular diseases was 17.9 million in 2020.

Sanofi S.A., Gedeon Richter, Pfizer, Bristol-Myers Squibb, Novartis, and Merck (MSD) are the major market players for the drug class ACE inhibitors.

Major indications for ACE Inhibitors are hypertension, heart failure, stroke, coronary heart disease, chronic kidney disease, and diabetes mellitus.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb Company (USA)
  • AbbVie Inc. (USA)
  • AstraZeneca (UK)
  • Merck (MSD) (USA)
  • Sanofi S.A. (France)
  • Pfizer Inc. (USA)

Adjacent Markets